No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia

Neuropsychopharmacology

Volumn 20, Issue 6, 1999, Pages 650-661

  Abi Dargham, Anissa ^a,b   Laruelle, Marc ^a,b   Krystal, John ^a   D'Souza, Cyril ^a   Zoghbi, Sami ^a   Baldwin, Ronald M ^a   Seibyl, John ^a   Mawlawi, Osama ^b   De Erasquin, Gabriel ^a   Charney, Dennis ^a   Innis, Robert B ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Columbia University ^*  (United States)

Author keywords

123I iomazenil; Benzodiazepine receptors; Schizophrenia; SPECT

Indexed keywords

BENZODIAZEPINE RECEPTOR; IODINE 123; IOMAZENIL;

ADULT; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; RECEPTOR DENSITY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; FLUMAZENIL; HUMANS; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RECEPTORS, GABA-A; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0033151377     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00107-9     Document Type: Article

References (50)

1. Abi-Dargham A., Gandelman M., Zoghbi S.S., Laruelle M., Baldwin R.M., Randall P., Zeaponce Y., Charney D.S., Hoffer P.B., Innis R.B. Reproducibility of SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil. J Nucl Med. 36:1995;167-175.
2. Abi-Dargham A., Krystal J., Laruelle M., Zoghbi S.S., D'Souza C., Brenner L., Sernyak M., Baldwin R.M., Zubal G., Hoffer P.B., Charney D.S., Innis R.B. SPECT imaging of benzodiazepine receptors in schizophrenics and healthy subjects. Soc Neurosci Abs. 20(part 1):1994;24. a.
3. 123I]iomazenil. Kinetic and equilibrium paradigms J Nucl Med. 35:1994;228-238. b.
4. Akbarian S., Huntsman M.M., Kim J.J., Tafazzoli A., Potkin S.G., Bunney W. Jr., Jones E.G. GABAA receptor subunit gene expression in human prefrontal cortex. Comparison of schizophrenics and controls Cereb Cortex. 5:1995;550-560. a.
5. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney W. Jr., Jones E.G. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry. 52:1995;258-266. b.
6. Beasley C.L., Reynolds G.P. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res. 24:1997;349-355.
7. Beer H.-F., Blauenstein P.A., Hasler P.H., Delaloye B., Riccabona G., Bangerl I., Hunkeler W., Bonetti E.P., Pieri L., Richards J.G., Schubiger P.A. In vitro and in vivo evaluation of iodine-123 Ro 16-0154. A new imaging agent for SPECT investigations of benzodiazepine receptors J Nucl Med. 31:1990;1007-1014.
8. Benes F.M., Khan Y., Vincent S.L., Wickramasinghe R. Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain. Synapse. 22:1996;338-349.
9. Benes F.M., McSparren J., Bird E.D., Vincent S.L., SanGiovanni J.P. Deficits in small interneurons in schizophrenic cortex. Arch Gen Psychiatry. 48:1991;996-1001.
10. Benes F.M., Vincent S.L., Alsterberg G., Bird E.D., SanGiovanni J.P. Increased GABAa receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci. 12:1992;924-929.
11. Benes F.M., Wickramasinghe R., Vincent S.L., Khan Y., Todtenkopf M. Uncoupling of GABA(A) and benzodiazepine receptor binding activity in the hippocampal formation of schizophrenic brain. Brain Res. 755:1997;121-129.
12. Bennett J.P., Enna S.J., Bylund D.B., Gillin J.C., Wyatt R.J., Snyder S.H. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry. 36:1979;927-934.
13. Bird E.D., Spokes E.G., Barnes J., MacKay A.V., Iversen L.L., Shepherd M. Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses. Lancet. 2:1977;1157-1158.
14. Braestrup C., Albrechten R., Squires R.F. High densities of benzodiazepine receptors in human cortical areas. Nature. 269:1977;702-704.
15. Busatto G.F., Pilowsky L.S., Costa D.C., Ell P.J., David A.S., Lucey J.V., Kerwin R.W. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Am J Psychiatry. 154:1997;56-63.
16. 18F]cyclofoxy and positron emission tomography J Cereb Blood Flow Metab. 13:1992;24-42.
17. Cross A.J., Crow T.J., Owen F. Gamma-aminobutyric acid in the brain in schizophrenia [letter]. Lancet. 1:1979;560-561.
18. Duvernoy H (1991): The Human Brain. Surface, Three-Dimensional Sectional Anatomy and MRI. New York, Sringer-Verlag Wien.
19. Friston K.J., Holmes A.P., Worsley K.J., Polin J.-P., Frith C.D., Frakowiak R.S.J. Statistical parametric maps in functional imaging. A general linear approach Hum Brain Mapping. 2:1995;189-210.
20. Gandelman M.S., Baldwin R.M., Zoghbi S.S., Zea-Ponce Y., Innis R.B. Evaluation of ultrafiltration for the free fraction determination of single photon emission computerized tomography (SPECT) radiotracers. β-CIT, IBF and iomazenil J Pharmaceutical Sci. 83:1994;1014-1019.
21. Gavish M., Weizman R., Becker D., Tanne Z. Effect of chronic haloperidol treatment on peripheral benzodiazepine binding sites in cerebral cortex of rats. Neural Transm. 74:1988;109-116.
22. Giardino L., Calza L., Piazza P.V., Amato G. Multiple neurochemical action of clozapine. A quantitative autoradiographic study of DA2, opiate and benzodiazepine receptors in the rat brain after long-term treatment J Neural Transm. 83:1991;189-203.
23. Hanada S., Mita T., Nishino N., Tanaka C. [3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci. 40:1987;259-266.
24. Jiang H, Robb RA (1992): A new approach to 3-D registration of multimodality images by surface matching. in Proceedings of the second conference on visualization in biomedical computing. Chapel Hill, NC.
25. Kawai R., Carson R.E., Dunn B., Newman A.H., Rice K.C., Blasberg R.G. Regional brain measurement of Bmax and KD with the opiate antagonist cyclofoxy. Equilibrium studies in the conscious rat J Cereb Blood Flow Metab. 11:1991;529-544.
26. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome scale (PANSS) for schizophrenia. Schiz Bull. 13:1987;261-276.
27. Kirk RE (1982): Experimental Design: Procedures for the Behavioral Sciences. Pacific Grove, California, Brooks/Cole Publishing Company.
28. Kiuchi Y., Kobayashi T., Takeuchi J., Shimizu H., Ogata H., Toru M. Benzodiazepine receptors increase in post-morten brain of chronic schizophrenics. Eur Arch Psych Neurol Sci. 239:1989;71-78.
29. 123I]iomazenil binding to benzodiazepine receptors in nonhuman primates. II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. J Cereb Blood Flow Metab. 14:1994;453-465.
30. 123I]iomazenil Eur J Pharmacol. 230:1993;119-123.
31. Lassen N.A. A reappraisal of the relative merits of SPECT and PET in the quantitation of neuroreceptors. The advantage of a longer half-life! Eur J Nucl Med. 23:1996;1-4.
32. 2 receptors in human brain. J Neurochem. 43:1984;1068-1071.
33. Munetz M., Benjamin S. How to examine patients using the abnormal involuntary movement scale. Hosp Comm Psychiatry. 39:1988;1172-1177.
34. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol Reports. 10:1962;799-812.
35. Pandey G.N., Conley R.R., Pandey S.C., Goel S., Roberts R.C., Tamminga C.A., Chute D., Smialek J. Benzodiazepine receptors in the post-mortem brain of suicide victims and schizophrenic subjects. Psychiatry Res. 71:1997;137-149.
36. Perry T.L., Buchanan J., Kish S., Hanssen S. γ-aminobutyric acid deficiency in brain of schizophrenic patients. Lancet. 1:1979;237-239.
37. Reynolds G.P., Czudek C., Andrews H.B. Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia. Biol Psychiatry. 27:1990;1038-1044.
38. Reynolds G.P., Stroud D. Hippocampal benzodiazepine receptors in schizophrenia. J Neural Transm. 93:1993;151-155.
39. Roberts E. An hypothesis suggesting that there is a deficit in the GABA system in schizophrenia. Neurosci Res Prog Bull. 10:1972;468-481.
40. Schröder J., Bubeck B., Demisch S., Sauer H. Benzodiazepine receptor distribution and diazepam binding in schizophrenia. An exploratory study Psychiat Res Neuroimaging. 68:1997;125-131.
41. Sherman A.D., Davidson A.T., Baruah S., Hegwood T.S., Waziri R. Evidence of glutamatergic deficiency in schizophrenia. Neurosci Letters. 121:1991;77-80.
42. Simpson M.D., Slater P., Deakin J.F., Royston M.C., Skan W.J. Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci Letters. 107:1989;211-215.
43. 3H]flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains. Is selective loss of glutamatergic neurons associated with major psychoses? Neurochem Res. 18:1993;219-223.
44. Stevens J.R. Gaba blockade, dopamine and schizophrenia. Int J Neurology. 10:1975;115-127.
45. Talairach J, Tournoux P (1988): Co-Planar Stereotactic Atlas of the Human Brain. Three-dimensional Proportional System: An Approach of Cerebral Imaging. New York, Theime Medical Publisher.
46. van Kammen D.P. γ-aminobutyric acid (Gaba) and the dopamine hypothesis of schizophrenia. Am J Psychiatry. 134:1977;138-143.
47. Woo T.U., Miller J.L., Lewis D.A. Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. Am J Psychiatry. 154:1997;1013-1015.
48. 123I]iomazenil. Implication for the reaction mechanism Int J Appl Radiat Isot. 45:1993;63-68.
49. 123I]iomazenil in human and nonhuman primates. Nucl Med Biol. 19:1992;5.
50. Zubal I.G., Harrell C., Woods S.W., Innis R.B., Hoffer P.B., Caride V.J., Zimmermann R.E. Comparison of quantitation linearity of three brain SPECT imaging instruments using Tc-99m and I-123. J Nucl Med. 31:1990;769-770.